<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646721</url>
  </required_header>
  <id_info>
    <org_study_id>DA1241_DM_Ib</org_study_id>
    <nct_id>NCT03646721</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM</brief_title>
  <official_title>A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the
      safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-lead ECGs</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in QTcF (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in blood pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in heart rate (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in oral body temperature (°C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Change from baseline in respiratory rate (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Incidence and severity of clinical findings on physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory testing</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Incidence and severity of clinical laboratory abnormality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Throughout study duration, i.e., about 10 weeks (Part1) and about 14-16 weeks (Part2), respectively</time_frame>
    <description>Incidence and severity of adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of DA-1241 (Cmax)</measure>
    <time_frame>Through the treatment period; 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma DA-1241 concentration (Tmax)</measure>
    <time_frame>Through the treatment period; 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (t½)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total systemic clearance after oral administration (CL/F)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Last dosing day AUCtau / First dosing day AUCtau)</measure>
    <time_frame>Through the treatment period; 9 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of DA-1241 excreted unchanged in the urine in each collection interval(Ae)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of DA-1241 excreted unchanged in the urine (Cum Ae)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage fraction of DA-1241 excreted unchanged in the urine in each collection interval(Fe)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative percentage fraction of DA-1241 excreted unchanged in the urine (Cum Fe)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR)</measure>
    <time_frame>Through the treatment period; 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Through the treatment period; 62 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2h-Postprandial glucose</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the measurements versus (vs) time curve(AUE)</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental AUEs after meal (iAUE)</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted mean glucose (WMG)</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental WMG (iWMG)</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated albumin</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Through the treatment period; 56 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of key metabolite(s) of DA-1241</measure>
    <time_frame>Through the treatment period; 41 days</time_frame>
    <description>Key metabolite(s) of DA-1241 will be assessed in blood and urine.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-1241</intervention_name>
    <description>[Part1] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.
[Part2] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.
(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)</description>
    <arm_group_label>[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)</arm_group_label>
    <arm_group_label>[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>[Part1] Administration once daily for 28 days. [Part2] Administration once daily for 56 days.</description>
    <arm_group_label>[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)</arm_group_label>
    <arm_group_label>[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>[Part2] Administration of Sitagliptin 100mg once daily for 56 days.</description>
    <arm_group_label>[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        &lt;Part 1&gt;

        Inclusion Criteria:

          1. Healthy male subjects

          2. Age ≥ 18 to ≤ 70 years of age.

          3. Body mass index (BMI) ≥ 18.5 to ≤ 29.9 kg/m2.

          4. Non-diabetic, fasting plasma glucose (FPG) of &lt; 100 mg/dL (measured with YSI at site;
             one repeat test is allowed)

          5. HbA1c &lt; 5.7 %

          6. Non-smoker smoker, defined as: Non-smoker for &gt;12 months (ie, subject has not smoked
             or used any tobacco product for the 12 months prior to the start of the study)
             confirmed by a negative nicotine/cotinine test.

          7. Male subjects must be surgically sterile, or engaged with partners of non-childbearing
             potential, or if engaged with partners of childbearing potential, the subject and his
             partner must be willing to use contraceptive methods until 3 months after the last day
             of IP administration. Males must not donate sperms during the study and until 3 months
             after the last day of IP administration.

          8. Upon review, agree to participate and sign informed consent

        Exclusion Criteria:

          1. Resting blood pressure (BP) &gt; 140/90 mmHg or &lt; 90/60 mmHg. Subjects BP may be
             re-checked.

          2. Participation in an investigational drug/device study within 30 days or 5 half-lives
             within the last dose of any study drug, whichever is longer.

          3. History of any serious adverse reaction or hypersensitivity to any of the
             investigational product components or medicinal products with similar chemical
             structure.

          4. Have significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders or
             abnormalities, or other major systemic disease that, according to the investigator,
             would unduly risk the subject's safety or may impact the conduct of the study.

          5. History of or acute significant gastrointestinal disorder (eg, peptic ulcers, severe
             GERD), gastric surgery, including surgical treatment for obesity (eg, bariatric
             surgery, gastric banding), gastric bypass or antrectomy or small bowel resection &gt;20cm
             or any disorder that would interfere with the swallowing, absorption, distribution,
             metabolism and excretion of the investigational product. Surgery for appendicitis is
             acceptable.

          6. Subject shows evidence of significant active neuropsychiatric disease, including
             taking prescription medication for such diseases (including anti-depressant
             /anti-anxiety medication),

          7. Presence of clinically significant physical, laboratory, or ECG findings at Screening
             that, in the opinion of the Investigator, may interfere with any aspect of study
             conduct or interpretation of results, or may present a safety issue to that particular
             subject. (Laboratory results may be re-checked once on a separate day per Investigator
             discretion)

          8. Long QT syndrome or family history of long QT syndrome or corrected QT interval (QTcF)
             &gt; 450 ms at screening.

          9. Liver function test results of AST and/or ALT ≥ 1.5 upper limit of normal (ULN).

         10. Subject had a history of vaso-vagal syncope within 5 years.

         11. History of any major surgery within 6 months.

         12. History of any active infection, other than mild viral illness within 30 days prior to
             dosing.

         13. Known history or positive test of hepatitis B surface antigen (HBsAg), hepatitis C
             antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or 2 (HIV-2)
             antibody.

         14. Subjects with a positive urine nicotine/cotinine dipstick test.

         15. History of alcohol abuse as judged by the Investigator within approximately 1 year.
             Average weekly alcohol intake &gt; 21 units/week or are unwilling to stop alcohol
             consumption from 24 hours prior to each dosing until discharged from the clinical
             research unit (CRU). Positive alcohol test at Screening. (One unit of alcohol equals
             about 250 mL of beer or lager, 100 mL of wine, or 35 mL of spirits).

         16. History of illicit drug abuse, within approximately 1 year or evidence of current use
             as judged by the Investigator. Positive drug test, including marijuana, at Screening.

         17. Donation or loss of &gt; 500 mL of blood within 56 days.

         18. Chronic use of over-the-counter or prescription medication within 7 or 14 days prior
             to dosing per Investigator's discretion (apart from vitamin/mineral supplements,
             occasional paracetamol, or birth control methods).

         19. Unable to comply with the safety monitoring requirements of this clinical study or is
             considered by the investigator to be an unsuitable candidate for the study.

        &lt;Part 2&gt;

        Inclusion Criteria:

          1. Male and female subjects with T2DM &gt; 6 months.

          2. Age ≥ 18 to ≤ 70 years of age.

          3. Body mass index (BMI) ≤ 35 kg/m2.

          4. On stable therapy with metformin monotherapy or metformin in combination with other
             oral antidiabetic drugs (OADs) ≥ 1 month. (OADs except metformin will be washed-out
             prior to the first dosing)

          5. HbA1c ≥ 6.5 to ≤ 10%

          6. Female and male subjects must agree to use highly effective methods of birth control
             until 120 days after the last day of IP administration, or must be surgically sterile
             or postmenopausal. Males must not donate sperm during the study and until 120 days
             after the last day of IP administration.

          7. Upon review, agree to participate and sign informed consent.

        Exclusion Criteria :

          1. A subject who has acute proliferative retinopathy or maculopathy, severe
             gastroparesis, and/or severe neuropathy, especially autonomic neuropathy, as judged by
             the Investigator.

          2. Recurrent major hypoglycemia or hypoglycemic unawareness or recent ketoacidosis, as
             judged by the Investigator.

          3. Persistent blood pressure (BP) systolic or diastolic &gt; 160/90 mmHg or &lt; 90/60 mmHg.
             Subjects BP may be re-checked per site SOP. Treatment with stable doses of
             antihypertensive medication for 2 months prior to screening are allowed.

          4. Pregnant or lactating women.

          5. Participation in an investigational drug/device study within 30 days or 5 half-lives
             within the last dose of any study drug, whichever is longer.

          6. History of any serious adverse reaction or hypersensitivity to any of the
             investigational product components or medicinal products with similar chemical
             structure.

          7. Current use of any prescribed or non-prescribed drugs (other than current treatment
             for diabetes mellitus or birth control methods) that are known to interfere with
             glucose or insulin metabolism, including but not limited to oral corticosteroids,
             GLP-1 receptor agonists, monoamine oxidase (MAO) inhibitors, growth hormone,
             non-selective β-blockers and lipid lowering medication. Lipid lowering medications
             will be washed-out prior to the first dosing if subjects take medication for primary
             prevention.

          8. History of administration or current use of thiazolidinediones (TZDs).

          9. Chronic use of acetaminophen, as acetaminophen is not allowed during the CGMS periods
             in the study.

         10. Unable to tolerate tape adhesive in the area of sensor placement.

         11. Subject has any unresolved adverse skin condition in the area of sensor placement (eg,
             psoriasis, rash, Staphylococcus infection).

         12. History of or acute significant gastrointestinal disorder (eg, peptic ulcers, severe
             GERD), gastric surgery, gastric bypass or antrectomy or small bowel resection or any
             disorder that would interfere with the swallowing, absorption, distribution,
             metabolism and excretion of the investigational product. Surgery for appendicitis is
             acceptable.

         13. History of renal disease or abnormal kidney function tests at Screening (eGFR &lt; 60
             mL/min/1.73m2 as estimated using the MDRD equation).

         14. Clinically significant abnormal laboratory test, in particular, elevated liver enzymes
             (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels &gt; 2 times
             the upper limit of normal (ULN)). (Laboratory results may be re-checked once on a
             separate day per Investigator discretion)

         15. Any history of heart disease, defined as symptomatic heart failure (New York Heart
             Association class III or IV), myocardial infarction, coronary artery bypass graft
             surgery, or angioplasty, unstable angina requiring medication, transient ischemic
             attack, cerebral infarct, or cerebral hemorrhage.

         16. History of any clinically or active significant gastrointestinal, cardiovascular,
             hematological, psychiatric, renal, hepatic, pancreatic or neurological abnormality
             that could interfere with the safety or results of this study as judged by the
             Investigator.

         17. Subject shows evidence of significant active neuropsychiatric disease. Subjects that
             are stable and controlled by stable doses of selective serotonin reuptake inhibitors
             (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), antipsychotics and
             lithium for ≥ 6 months prior to screening are allowed.

         18. Presence of clinically significant physical or ECG findings (eg, QTcF &gt; 450 msec for
             males, QTcF &gt; 470 msec for females, left bundle branch block (LBBB)) at Screening
             that, in the opinion of the Investigator, may interfere with any aspect of study
             conduct or interpretation of results, or may present a safety issue to that particular
             subject.

         19. History of any major surgery within 6 months.

         20. History of any active infection, other than mild viral illness within 30 days prior to
             the first dosing.

         21. Known history or positive test of hepatitis B surface antigen (HBsAg), hepatitis C
             antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or 2 (HIV-2)
             antibody.

         22. Smoking &gt; 10 cigarettes per day or equivalent use of any tobacco product (eg, nicotine
             patch) within 6 months prior to Screening. Subjects must be able to refrain from
             smoking during each in-house period.

         23. History of alcohol abuse as judged by the Investigator within approximately 1 year.
             Average weekly alcohol intake &gt; 21 units/week (males) and &gt; 14 units/week (females) or
             are unwilling to stop alcohol consumption from 24 hours prior to each check-in for
             in-house and outpatient visits and throughout the in-house periods until discharged
             from the clinical research unit (CRU) and are unwilling to limit alcohol consumption
             during outpatient periods. Positive alcohol test at Screening. (One unit of alcohol
             equals about 250 mL of beer or lager, 100 mL of wine, or 35 mL of spirits).

         24. History of illicit drug abuse, within approximately 1 year or evidence of current use
             as judged by the Investigator. Positive drug test, including marijuana, at Screening.

         25. Donation or loss of &gt; 500 mL of blood within 56 days.

         26. Unable to comply with the safety monitoring requirements of this clinical study or is
             considered by the investigator to be an unsuitable candidate for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiyoon Jeong</last_name>
    <phone>+82.2.920.8215</phone>
    <email>jyjeong@donga.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Willard, MD</last_name>
      <phone>619-943-6328</phone>
      <phone_ext>217</phone_ext>
      <email>Julie.Willard@prosciento.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria I. Bermudez, MD</last_name>
      <email>mbermudez@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Fein, MD</last_name>
      <email>mfein@highpointctc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Klaff, MD</last_name>
      <email>ljklaff@rainier-research.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

